HRE is sufficient to produce motor neuron degeneration in mice (

Results
Generation and Characterization of AR YAC Transgenic Mice
To produce an accurate model of SBMA, we chose to obtain a yeast artificial chromosome (YAC) containing the ‫001ف‬ kb human AR gene. Characterization of a 450 kb YAC that contains the human AR gene has already been described (La Spada et al., 1998). These studies indicated that the AR gene is centrally located within this YAC, making it likely that the regulatory elements required for proper temporal and spatial expression within the central nervous system (CNS) would be present. To introduce an expanded CAG repeat into this construct, we took advantage of the highly efficient homologous recombination machinery of yeast and, using the pop-in/pop-out approach, obtained an AR YAC construct carrying a properly targeted CAG100 repeat (Sopher et al., 2000) ( Figure 1A ). Since microinjection of analysis indicated that human AR transgene levels in all two lanes on the left correspond to HEK293T cells transfected with either an AR20 expression construct (AR20 ctrl) or an expanded AR125 expression construct (AR125 ctrl). AR20 migrates at ‫011ف‬ kDa, while AR125 migrates at ‫031ف‬ kDa. The five lanes on the right correspond to liver lysates from a nontransgenic mouse (ntg); two as described for part (C). Although a crossreacting band comigrates AR20 mice (AR20; line C3A on the left and line C9B on the right); at ‫521ف‬ kDa in ntg and AR20 samples, the greater intensity of the and two AR100 mice from line C25 (AR100). Intense bands migrating signal in the AR100 lanes is indicative of full-length AR100 protein at ‫011ف‬ kDa and ‫521ف‬ kDa for AR20 and AR100 are indicated, expression. This result is corroborated with a different AR antibody respectively, by the upper arrows. A crossreacting band at ‫58ف‬ kDa (Supplemental Figure S1 at http://www.neuron.org/cgi/content/full/ (lower arrow) verifies equivalent loading. There is no immunoreactiv-41/5/687/DC1). While no immunoreactivity is observed in the stackity in the stacking area (bracketed with asterisk).
ing portion of the gel (bracket; one asterisk), faint immunoreactivity (D) Full-length AR protein is detected as a soluble monomer both is apparent in the left AR100 lane at the top of the separating gel in AR20 and AR100 transgenic mice in the CNS. Protein was isolated (bracket; two asterisks) and may be consistent with microaggrefrom transiently transfected HEK293T cells or from mouse brain and gates or oligomers. Immunoblot analysis of nuclear fractions yielded then immunoblotted with antibody H-280. The lanes and arrows are similar results (data not shown).
attempting to walk (Supplemental Movie S1 at http:// While male C25 AR100 and male C32 AR100 mice proage of the three runs was rounded to the nearest 0.1.
gress through all three stages in the course of 1-2 years, female C25 AR100 and female C32 AR100 mice never show the full expression of the disease phenotype (Table  four lines are close to one another and are relatively 2). Thus, in the case of our SBMA mouse model, the physiological, varying from 30%-100% of endogenous expression of the phenotype is gender dependent. Felevels (Table 1) . We performed Western blot analysis to male AR100 mice are mildly affected, however, as they verify the expression of full-length human AR protein, are often smaller in size and weight, and in the case of first in liver ( Figure 1C ) and then in brain ( Figure 1D) . the higher-expressing C25 line, occasionally show signs Soluble monomeric AR protein was readily detectable of hindlimb atrophy beyond 2 years of age. The presence in both of these tissues, regardless of the length of of a phenotype in female AR100 mice is not unexpected, the polyglutamine repeat expansion, and was confirmed as many female SBMA carriers complain of muscle with another antibody (Supplementary Figure . immunoblots revealed no evidence for typical aggreIn addition to charting the course of the neurological gates in AR100 mice, although increased immunostainphenotype by examination and visual inspection, we ing at the top of separating gels was occasionally noted determined when AR100 mice first show behavioral ab-( Figure 1D ). We then immunostained sections from the normalities in gait and muscle strength testing paracentral nervous system (CNS) of transgenic and nondigms. While footprint analysis performed on nontranstransgenic mice to determine the pattern of expression genic and C25 AR100 mice at 6.5 months revealed of the transgene. We observed marked expression of similar stride lengths (p ϭ 0.55), analysis at 11 months human AR protein in the anterior horn cells of the spinal indicated that significant differences in stride length cord, cranial nerve nuclei V (motor) and VII in the brainmeasurements exist prior to the development of visible stem, the cortex, the hypothalamus, and the olfactory gait abnormalities (p Ͻ 0.05) ( Figure 2E ). To evaluate bulb (presented later in Figure 4) . No expression of humuscle strength, we subjected C25 AR100 mice and man AR was observed in motor layer V of the cortex, their nontransgenic littermates to the "hanging wire" nor in the cerebellum or hippocampus (data not shown).
test (Crawley, 1999) . While AR100 mice were not able to hold their bodies up on an inverted cage lid as long as age-matched littermates at 6.5 months ( Figure 2F ), AR YAC CAG100 Mice Exhibit a Progressive this performance difference was not significant (p ϭ Motor Deficit 0.30). By 11 months of age, however, control littermates We evaluated the health and behavioral phenotype of displayed "latency to fall" times that were nearly 3.5 AR YAC transgenic mice and noted abnormalities in times longer than AR100 mice (p Ͻ 0.01) ( Figure 2F ). both AR100 lines. In the higher-expressing AR100 C25 Thus, behavioral abnormalities in gait and muscle line, the first sign of a phenotypic difference is growth strength appear in the AR100 mice just before they show retardation beginning at about 8 months of age. By 10 a phenotype. Similar studies performed on AR20 male months of age, the difference in body size and weight mice revealed performance results comparable to that is readily apparent (Figure 2A ). Weight loss is soon acof controls (data not shown). companied by proximal muscle weakness, producing a curvature of the spine that gives the AR100 mice an obvious kyphotic appearance ( Figure 2B) (E) AR 100 mice show decreased stride length prior to visible gait impairment. Groups of AR100 line C25 mice and nontransgenic littermates (n ϭ 6-8/group) were subjected to footprint analysis, and mean stride lengths were calculated and compared between the two groups. By 11 months of age, the AR100 mice displayed significantly shorter stride lengths. (F) AR100 mice appear weaker than controls in the hanging wire test. Groups of AR100 line C25 mice and nontransgenic littermates (n ϭ 6-8/group) were suspended from their cage lids with forepaws and hindpaws gripping the bars and the time until they fell measured. While a slight trend in falling off more quickly is noted in AR100 mice at 6.5 months of age, the ability of AR100 mice to hang on to the cage lid only becomes significantly impaired at later ages. pathology, we performed enzymatic staining. NADHfibers ( Figure 3F ). NCAM-stained sections from nontransgenic controls were negative for sarcoplasmic exstained sections from control mice showed a scattered distribution of type II muscle fibers ( Figure 3C ), while pression ( Figure 3E ). The NADH and NCAM staining data strongly support the conclusion that AR100 mice are NADH staining of AR100 muscle sections revealed large areas of fiber type grouping ( Figure 3D ). Immunostaining suffering muscle atrophy due to denervation. To assess whether AR100 mice display motor neuron degenerawith an antibody directed against neural cell adhesion molecule (NCAM), a protein known to be upregulated tion, we reviewed lumbar spinal cord sections stained with a basic dye (Richardson's). While we noted the during muscle renervation ( gates." Although we did not observe nuclear inclusions that they were degenerating ( Figure 3H ). Taken together, in motor neurons, we did detect punctate staining in the these findings indicate that AR YAC CAG100 transgenic nuclei of spinal cord astrocytes in AR100 mice but not mice recapitulate the muscle atrophy/motor neuron deage-matched nontransgenic or AR20 controls (Figures generation phenotype seen in SBMA.
4D-4F), suggesting that AR100 nuclear aggregates form in nonneuronal cells. In CNS sections from the AR100 mice, we noted the presence of punctate nuclear aggrePolyglutamine-Expanded AR Protein Accumulates gates in the dorsal lateral hypothalamus and tectum in the Nucleus but Does Not Form Nuclear ( Figure 4G ; data not shown). Neuropathology examinaAggregates in Pathologically Affected Regions tion of these regions failed to indicate any degenerative To determine the subcellular localization of polyglutachanges. Immunostaining of brainstem sections, howmine-expanded AR protein, we performed immunohisever, revealed diffuse nuclear staining of neurons that tochemistry on CNS sections using AR-specific antibodcomprise the motor nucleus of cranial nerve V and craies. Immunostaining of motor neurons revealed only nial nerve VII ( Figure 4H ; data not shown). We also surfaint nuclear staining in AR20 controls while showing veyed other nonneuronal tissues and observed obvious dramatic nuclear accumulation of human AR protein in nuclear inclusions in AR100 muscle and liver ( Figure 4I ; AR100 mice (Figures 4A-4C) . However, in no case did we detect the formation of classic nuclear aggregates Supplemental Figure S2 at http://www.neuron.org/cgi/ Figure 6B ). We observed a further decrease in VEGF 164 message levels in AR100 mice at this age. Thus, RT-PCR analysis of VEGF 164 expression revealed a specific decrease in presymptomatic AR100 mice. To independently confirm the VEGF downregulation, we chose to measure VEGF protein levels by ELISA. The ELISA method employed an antibody that detects all three VEGF isoforms. VEGF 188 is typically not present in protein lysates, however, as it remains bound to the extracellular matrix (Ferrara et al., 2003) . ELISA measurements performed on spinal cord lysates obtained from 8-month-old nontransgenic, AR20, and AR100 mice showed a significant reduction in VEGF 120 ϩ 164 levels in AR100 male mice and a significant increase in VEGF 120 ϩ 164 levels in AR20 male mice ( Figure 6C ). We also measured VEGF 120 ϩ 164 protein levels in spinal cord lysates from female mice and observed no meaningful changes ( Figure 6C ). The ELISA results thus confirmed the VEGF 164 expression decreases observed by real-time RT-PCR in the spinal cords of presymptomatic AR100 SBMA mice.
To assess the biological significance of the VEGF 164 downregulation, we employed a well-established motor neuron cell culture model of AR polyglutamine neurotox- VEGF gene expression in SBMA motor neuron degenerTo confirm that reduction of VEGF 164 also occurs at ation. Thus, in the case of ALS and SBMA, two distinct the protein level, we performed a VEGF ELISA assay on motor neuron diseases, the ability of the motor neuron spinal cord lysates from 8-month-old AR100 mice and to adapt to cellular stress and injury may rest upon detected a significant reduction in VEGF 120 ϩ 164. the ability to fully activate VEGF gene expression. Our While the ELISA assay detects both the 120 and 164 results, together with previous studies in mice and in isoforms, most of the AR100 reduction likely reflects a humans, suggest that VEGF may play a pivotal role in drop in VEGF 164, as AR20 VEGF 120 ϩ 164 protein motor neuron degeneration. As no meaningful therapies levels and AR20 VEGF RNA levels for all isoforms are exist for motor neuron diseases, an important goal will elevated. AR20 VEGF 164 RNA levels, however, differ be to determine if VEGF delivery to motor neurons in little from nontransgenic controls. with all samples measured in triplicate. Statistical significance was determined by Student's t test or ANOVA.
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